Search

everythinglearnresearchcommunity

for

Search:↓

Discussing results, side effects and potential sources of pyrilutamide for hair loss treatment alongside RU58841 and other treatments such as Minoxidil and finasteride.

The conversation is about the availability of hair loss treatments Breezula, SM04554, Follica FOL-004, and Follicum FOL-005 in Canada after FDA approval, including potential delays, loopholes for obtaining them, and insurance coverage.

The user increased their steroid dosage and noticed hair shedding, so they adjusted their regimen by reducing steroid doses and adding oral dutasteride. They are also experimenting with combining RU-58841 and KX-826/pyrilutamide in minoxidil to address hair loss.

The user was rejected from participating in a clinical trial for an extended-release oral Minoxidil due to having rheumatoid arthritis, despite initially being accepted. They had stopped using Dutasteride and Minoxidil to qualify but continued using other treatments like RU58841 and red light therapy.

A user experienced hair thinning and increased shedding after starting a high-dose B-complex supplement while using Minoxidil and RU58841. They are seeking advice on whether others have had similar issues with high doses of Vitamin B3 and B5.

The conversation discusses the high prices of hair loss treatments, specifically cb-03-01 and KY19382. It also mentions the use of Minoxidil, finasteride, and RU58841.

Stress can lead to hair loss by affecting hair-follicle stem cells, and this loss is harder to recover from if one has male pattern baldness (MPB). Treatments like finasteride and minoxidil are used to address hair loss, but stress-related hair loss differs from androgenic alopecia.

The user is seeking an alternative solvent for pyrilutamide due to skin irritation from ethanol and propylene glycol. They experienced similar issues with topical minoxidil.

PP405 is a new hair loss treatment showing early promise with a 20% hair density increase, but skepticism exists due to past failures of similar treatments like Pyrilutamide, RU58841, and Bimatoprost. Users debate its potential effectiveness, with some hopeful due to Google's involvement, while others urge caution without more evidence.

The user experienced significant hair regrowth using KX-826 (pyrilutamide) 0.9% over one year, despite initial shedding phases. They reported no side effects and have stabilized hair loss with consistent use.

. CumsOnYourFeet69 has been discussing a new treatment called CosmeRNA which claims to target the root cause of male pattern baldness, and is considering using it in conjunction with Minoxidil instead of Finasteride due to possible side effects. Replies have highlighted that the efficacy of this treatment is still unknown, but it could be used as an effective maintenance option if successful.

The conversation is about seeking information on GT20029 from Kintor Pharmaceutical as a potential hair loss cure and inquiring about experiences with CosmeaRNA.

User tries dermapen for hair loss and plans to use non-mainstream topicals like c60, ghk-cu, and ptd-dbm with valproic acid. They also use a head massager and modified LLLT belt for additional treatment.

A user is interested in Absci's AI-driven antibody platform, ABS-201, for treating androgenetic alopecia, which shows promising preclinical results and potential for hair regrowth and pigmentation restoration. However, concerns are raised about the drug's development timeline and its advantages compared to existing treatments.

Pelage Pharmaceuticals' PP405 aims to treat hair loss by reactivating dormant hair follicle stem cells, showing promising results in early trials. The company plans to present their findings at the American Academy of Dermatology Annual Meeting in 2026.

A Swiss product called Redensyl, which is supposed to target hair follicle stem cells and has recently been marketed in Europe. The post inquires if anyone has had any experience with the product.

Kintor Pharma completed a successful Phase II clinical trial for KX-826, a treatment for androgenetic alopecia. KX-826 is similar to finasteride with minor side effects and is more backed than Cosmerna.

Kintor is producing a cosmetic with KX826, starting at 0.5% concentration and moving to 1%. The 0.5% concentration wasn't as effective as minoxidil and finasteride, but the 1% concentration shows promise.

Pelage plans to release phase 2 results and start phase 3 trials for PP405 in 2050, but skepticism remains due to past delays and unfulfilled promises. Users express frustration over the lack of progress in hair loss treatments, mentioning Minoxidil, finasteride, RU58841, CB-03-01, and Fluridil.

PP405 is a potential hair loss treatment showing promise, especially for men with severe balding. Some are hopeful it will be a game-changer for those who cannot tolerate finasteride or minoxidil, despite skepticism about the outcomes.

Scientists discover SCUBE3 molecule for potential baldness cure. Mice used in research for hair growth signaling.

Hair loss treatments discussed include Minoxidil, Finasteride, and RU58841. Pyrilutamide Phase 2 results are expected in June 2022, with hopes for a better alternative to current treatments.

Botox in scalp muscles is being discussed as a potential hair loss treatment. Minoxidil, finasteride, and RU58841 are also mentioned as treatments.

The user started using pyrilutamide for hair loss on January 24, applying 1ml daily without other treatments, and after 10 days noticed reduced hair shedding and improved hair quality, with plans to continue for at least 6 months. They experienced chest pain initially, which could be related to starting methylphenidate or pyrilutamide, but the pain has since subsided.

Using a combination of micro-needling and exosome injections as a potential treatment for male pattern baldness, which could result in 50% or more regrowth.

The user experienced microinflammation on the crown after using mometasone furoate (Nasonex) nasal spray. They are seeking information on the relationship between this corticosteroid and hair loss.

Verteporfin and FAK inhibitors being looked at as potential treatments for hair regeneration, with updates on the unofficial off-label human trial being discussed.

Replicel's results were delayed, but Shiseido might share data at BioJapan on October 11. Users are hopeful for new treatments like RCH-01, potentially eliminating the need for finasteride or minoxidil.

The conversation is about the approval of Clascoterone (Winlevi) in Canada for hair loss treatment. One user expressed skepticism about its effectiveness due to low concentration.

Hair loss is linked to a higher rate of body dysmorphic disorder (BDD), OCD, and depression. Finasteride and dutasteride are not linked to increased suicidal risk, though some users report mental health side effects.